Gabapentin
Product Images NDC 66116-407

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Gabapentin (NDC 66116-407). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Medvantx, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Chemical Structure (38d9d7d7 9f81 4517 Acee E34232215800 01)

Chemical structure of the active ingredient gabapentin, showing a cyclohexane ring with an amino group and a carboxymethyl side chain.*

FDA Label Image

Figure 1. Weekly Mean Pain Scores (observed Cases In Itt Population): Study 1 (38d9d7d7 9f81 4517 Acee E34232215800 02)

A line graph comparing mean pain scores over an 8-week period between a placebo group and a group receiving Gabapentin at 3600 mg/day. The x-axis denotes weeks from baseline to week 8, and the y-axis shows mean pain scores ranging from 0 to 10. The graph indicates a 4-week dose titration period followed by a 4-week fixed dose period, with Gabapentin showing a significant reduction in pain scores compared to placebo (p < 0.01).*

FDA Label Image

Figure 2. Weekly Mean Pain Scores (observed Cases In Itt Population): Study 2 (38d9d7d7 9f81 4517 Acee E34232215800 03)

A line graph depicting mean pain scores over weeks for three groups: placebo, Gabapentin 1800 mg/day, and Gabapentin 2400 mg/day. The x-axis represents weeks including baseline, week 1 to week 7; the y-axis shows mean pain scores from 0 to 10. The graph distinguishes a 3-week dose titration period and a 4-week fixed dose period, with Gabapentin groups showing substantially lower pain scores compared to placebo, with statistical significance indicated at p < 0.01.*

FDA Label Image

Figure 3. Proportion Of Responders (patients With ≥50% Reduction In Pain Score) At Endpoint: Controlled Phn Studies (38d9d7d7 9f81 4517 Acee E34232215800 04)

A bar chart comparing the percentage of responders at endpoint between placebo (PBO) and various doses of Gabapentin (GBP) in two studies. Study 1 shows 12% responders for PBO and 29% for GBP 3600, with statistical significance. Study 2 shows 14% responders for PBO and higher percentages for GBP 1800, 2400, and 3600 doses, reaching up to 34%, also with statistical significance.*

FDA Label Image

Figure 4. Responder Rate In Patients Receiving Gabapentin Expressed As A Difference From Placebo By Dose And Study (38d9d7d7 9f81 4517 Acee E34232215800 05)

A scatter plot comparing differences (%) across three studies labeled a, b, and c, against daily doses in milligrams (mg) ranging from 600 to 1800 mg. The plot shows data points for each study at various dose levels, illustrating variations in difference percentages by study and dose.*

FDA Label Image

Gabapentin 300mg 60 Capsules (38d9d7d7 9f81 4517 Acee E34232215800 06)

Gabapentin Capsules, USP 300 mg, 60 capsules bottle label by MedVantx, Inc. The label includes storage instructions at controlled room temperature (20°-25°C, 68°-77°F) with permitted excursions, directions to see package insert for dosage, and a contact phone number for refill assistance. It states the product is Rx only, a sample not for sale, and provides manufacturing and distribution information.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.